Assignee
CARDIFF ONCOLOGY INC
US·3 granted patents·17 pending applications·0 citations·filing 2019–2025
Top patents by PatentIndex Score
20 records- 0184US12263173B2PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancerCARDIFF ONCOLOGY INC·Filed 2024·Granted Apr 1, 2025·0 cites·20 claims
- 0284US12144813B2PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancerCARDIFF ONCOLOGY INC·Filed 2024·Granted Nov 19, 2024·0 cites·16 claims
- 0383US2025101092A1Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancerCARDIFF ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 0480US2025057847A1Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancerCARDIFF ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 0575US2024101656A1Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancerCARDIFF ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 0675US2025223348A1Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancerCARDIFF ONCOLOGY INC·Filed 2025·Application pending·0 cites
- 0768US2026069596A1Use of plk1 inhibitor as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancerCARDIFF ONCOLOGY INC·Filed 2025·Application pending·0 cites
- 0859US11957677B2Cancer treatment using FGFR inhibitors and PLK1 inhibitorsCARDIFF ONCOLOGY INC·Filed 2022·Granted Apr 16, 2024·0 cites·18 claims
- 0956US2026076970A1Cancer treatment using mtdp inhibitors and plk1 inhibitorsCARDIFF ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 1054US2024197730A1Cancer treatment using parp inhibitors and plk1 inhibitorsCARDIFF ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 1154US2023183814A1Predictive biomarkers for onvansertib treatmentCARDIFF ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 1253US2026092327A1Methods of monitoring mutations in treatment of colorectal cancerCARDIFF ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 1353US2025275978A1Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancerCARDIFF ONCOLOGY INC·Filed 2025·Application pending·0 cites
- 1448US2025017933A1Cancer treatment using lsd1 inhibitors and plk1 inhibitorsCARDIFF ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 1548US2023113501A1Treatment of leukemias and lymphomas with combinations of bcl-2 inhibitors and plk1 inhibitorsCARDIFF ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 1648US2023167505A1Circulating tumor dna as a biomarker for leukemia treatmentCARDIFF ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 1746US2022184086A1Plk1 inhibitors and psa levels in prostate cancerCARDIFF ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 1846US2022143021A1Onvansertib for inhibiting non-adrenergic contraction of smooth muscle and prostate cell proliferationCARDIFF ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 1945US2021222228A1Plk1 target phosphorylation status and treatment of cancer with plk1 inhibitorsCARDIFF ONCOLOGY INC·Filed 2019·Application pending·0 cites
- 2045US2023172935A1Methods of monitoring kras mutationsCARDIFF ONCOLOGY INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CARDIFF ONCOLOGY INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →